Trial Profile
A Phase II Trial of Combination Irinotecan and Capecitabine as Second-Line Treatment for Patients With Locally Advanced/Metastatic Biliary Tract Cancers Who Progressed or Intolerant to Front-Line Gemcitabine and Platinum Combination
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 30 Mar 2016 New trial record